349 related articles for article (PubMed ID: 32911849)
1. iRhom2: An Emerging Adaptor Regulating Immunity and Disease.
Al-Salihi MA; Lang PA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911849
[TBL] [Abstract][Full Text] [Related]
2. ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).
Weskamp G; Tüshaus J; Li D; Feederle R; Maretzky T; Swendemann S; Falck-Pedersen E; McIlwain DR; Mak TW; Salmon JE; Lichtenthaler SF; Blobel CP
J Biol Chem; 2020 Mar; 295(13):4350-4358. PubMed ID: 32060096
[TBL] [Abstract][Full Text] [Related]
3. Identification of Molecular Determinants in iRhoms1 and 2 That Contribute to the Substrate Selectivity of Stimulated ADAM17.
Zhao Y; Dávila EM; Li X; Tang B; Rabinowitsch AI; Perez-Aguilar JM; Blobel CP
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361585
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of rhomboid-like pseudoproteases in inflammatory and innate immune responses.
Luo WW; Shu HB
FEBS Lett; 2017 Oct; 591(20):3182-3189. PubMed ID: 28815577
[TBL] [Abstract][Full Text] [Related]
5. Novel functions of inactive rhomboid proteins in immunity and disease.
Geesala R; Issuree PD; Maretzky T
J Leukoc Biol; 2019 Oct; 106(4):823-835. PubMed ID: 31369701
[TBL] [Abstract][Full Text] [Related]
6. Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.
Tang B; Li X; Maretzky T; Perez-Aguilar JM; McIlwain D; Xie Y; Zheng Y; Mak TW; Weinstein H; Blobel CP
FASEB J; 2020 Apr; 34(4):4956-4969. PubMed ID: 32103528
[TBL] [Abstract][Full Text] [Related]
7. Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17.
Maney SK; McIlwain DR; Polz R; Pandyra AA; Sundaram B; Wolff D; Ohishi K; Maretzky T; Brooke MA; Evers A; Vasudevan AA; Aghaeepour N; Scheller J; Münk C; Häussinger D; Mak TW; Nolan GP; Kelsell DP; Blobel CP; Lang KS; Lang PA
Sci Signal; 2015 Nov; 8(401):ra109. PubMed ID: 26535007
[TBL] [Abstract][Full Text] [Related]
8. iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells.
Sieber B; Lu F; Stribbling SM; Grieve AG; Ryan AJ; Freeman M
J Cell Sci; 2022 Sep; 135(17):. PubMed ID: 35971826
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE.
Adrain C; Zettl M; Christova Y; Taylor N; Freeman M
Science; 2012 Jan; 335(6065):225-8. PubMed ID: 22246777
[TBL] [Abstract][Full Text] [Related]
10. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling.
Li X; Maretzky T; Weskamp G; Monette S; Qing X; Issuree PD; Crawford HC; McIlwain DR; Mak TW; Salmon JE; Blobel CP
Proc Natl Acad Sci U S A; 2015 May; 112(19):6080-5. PubMed ID: 25918388
[TBL] [Abstract][Full Text] [Related]
11. The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.
Urriola-Muñoz P; Li X; Maretzky T; McIlwain DR; Mak TW; Reyes JG; Blobel CP; Moreno RD
J Cell Physiol; 2018 Mar; 233(3):2247-2256. PubMed ID: 28703301
[TBL] [Abstract][Full Text] [Related]
12. The iRhom homology domain is indispensable for ADAM17-mediated TNFα and EGF receptor ligand release.
Düsterhöft S; Kahveci-Türköz S; Wozniak J; Seifert A; Kasparek P; Ohm H; Liu S; Kopkanova J; Lokau J; Garbers C; Preisinger C; Sedlacek R; Freeman M; Ludwig A
Cell Mol Life Sci; 2021 Jun; 78(11):5015-5040. PubMed ID: 33950315
[TBL] [Abstract][Full Text] [Related]
13. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding.
Maretzky T; McIlwain DR; Issuree PD; Li X; Malapeira J; Amin S; Lang PA; Mak TW; Blobel CP
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11433-8. PubMed ID: 23801765
[TBL] [Abstract][Full Text] [Related]
14. iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function.
Brooke MA; Etheridge SL; Kaplan N; Simpson C; O'Toole EA; Ishida-Yamamoto A; Marches O; Getsios S; Kelsell DP
Hum Mol Genet; 2014 Aug; 23(15):4064-76. PubMed ID: 24643277
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insight on the role of iRhom2-TNF-α-BAFF signaling pathway in various autoimmune disorders.
Dwivedi SD; Shukla R; Yadav K; Rathor LS; Singh D; Singh MR
Adv Biol Regul; 2024 May; 92():101011. PubMed ID: 38151421
[TBL] [Abstract][Full Text] [Related]
16. Status update on iRhom and ADAM17: It's still complicated.
Düsterhöft S; Babendreyer A; Giese AA; Flasshove C; Ludwig A
Biochim Biophys Acta Mol Cell Res; 2019 Oct; 1866(10):1567-1583. PubMed ID: 31330158
[TBL] [Abstract][Full Text] [Related]
17. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis.
Issuree PD; Maretzky T; McIlwain DR; Monette S; Qing X; Lang PA; Swendeman SL; Park-Min KH; Binder N; Kalliolias GD; Yarilina A; Horiuchi K; Ivashkiv LB; Mak TW; Salmon JE; Blobel CP
J Clin Invest; 2013 Feb; 123(2):928-32. PubMed ID: 23348744
[TBL] [Abstract][Full Text] [Related]
18. Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids.
Matthews AL; Noy PJ; Reyat JS; Tomlinson MG
Platelets; 2017 Jun; 28(4):333-341. PubMed ID: 27256961
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of iRhom2 Controls Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE.
Cavadas M; Oikonomidi I; Gaspar CJ; Burbridge E; Badenes M; Félix I; Bolado A; Hu T; Bileck A; Gerner C; Domingos PM; von Kriegsheim A; Adrain C
Cell Rep; 2017 Oct; 21(3):745-757. PubMed ID: 29045841
[TBL] [Abstract][Full Text] [Related]
20. Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis.
Li X; Maretzky T; Perez-Aguilar JM; Monette S; Weskamp G; Le Gall S; Beutler B; Weinstein H; Blobel CP
J Cell Sci; 2017 Mar; 130(5):868-878. PubMed ID: 28104813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
